High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit

This publication has 19 references indexed in Scilit:

• Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein
  Circulation, 2003
• Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle Cells
  Circulation, 2003
• Local Generation of C-Reactive Protein in Diseased Coronary Artery Venous Bypass Grafts and Normal Vascular Tissue
  Circulation, 2003
• Increased Thrombosis After Arterial Injury in Human C-Reactive Protein–Transgenic Mice
  Circulation, 2003
• Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)
  The American Journal of Cardiology, 2003
• C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events
  Circulation, 2003
• Markers of Inflammation and Cardiovascular Disease
  Circulation, 2003
• Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
  New England Journal of Medicine, 2002
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
  JAMA, 2001
• Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men
  New England Journal of Medicine, 1997